This study is designed to monitor the long-term safety of people who have previously received certain cell or gene therapies from AstraZeneca. Specifically, it will follow participants who received AZD5851 in study NCT06084884 or AZD0754 in study NCT06267729. The main goal is to track any specific side effects (adverse events) for up to 15 years after your last treatment. You may be able to join if you are 18 years or older, have received a cell or gene therapy in another AstraZeneca study, and provide your informed consent. The study is currently enrolling participants.

Study design

This is an observational study, meaning researchers will monitor participants without providing new treatments. It aims to enroll 64 participants across multiple centers and countries.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 15 years after their last cell or gene therapy treatment to monitor for specific side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.